Current Report Filing (8-k)

Date : 03/15/2019 @ 9:03PM
Source : Edgar (US Regulatory)
Stock : Adhera Therapeutics Inc. (ATRX)
Quote : 0.18  0.0 (0.00%) @ 2:29PM

Current Report Filing (8-k)












Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of Earliest Event Reported): March 11, 2019


Adhera Therapeutics, Inc.


(Exact name of registrant as specified in its charter)


Delaware   000-13789   11-2658569

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)


4721 Emperor Boulevard, Suite 350

Durham, North Carolina

(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: 919-578-5901




Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company [  ]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]







Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On March 11, 2019, Eric Teague, the Chief Financial Officer of Adhera Therapeutics, Inc. (the “Company”), submitted his resignation as the Chief Financial Officer of the Company and from any other positions (whether as an officer, director or otherwise) that he may hold with the Company or any of its subsidiaries, effective at the close of business on March 22, 2019. Mr. Teague resigned to pursue other business and personal opportunities. The Company has commenced a search to replace Mr. Teague, and it expects to appoint a successor within the coming weeks. The Company anticipates that Mr. Teague will be available to assist in the transition of his ongoing activities on behalf of the Company to his successor following the effective date of his resignation.







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Adhera Therapeutics, Inc.
March 15, 2019 By: /s/ Robert C. Moscato, Jr.
  Name:  Robert C. Moscato, Jr.
  Title: Chief Executive Officer





Adhera Therapeutics Inc. (USOTC:ATRX)
Historical Stock Chart

1 Year : From Jul 2018 to Jul 2019

Click Here for more Adhera Therapeutics Inc. Charts.

Adhera Therapeutics Inc. (USOTC:ATRX)
Intraday Stock Chart

Today : Thursday 18 July 2019

Click Here for more Adhera Therapeutics Inc. Charts.

Latest ATRX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.